© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
Inflammation & Infection
Noninfectious uveitis, uveitic macular oedema: A synopsis of frontline therapies
July 12, 2022
Dr Steven Yeh provides a brief overview of available therapies for noninfectious uveitis and uveitis macular oedema.
Enrolment begins in Phase 2 study for therapeutic for persistent corneal epithelial defects
July 10, 2022
Kiora Pharmaceuticals announced it has enrolled the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with PCED, a rare ocular surface condition characterized by non-healing wounds on the eye surface.
Ebola, other viruses may be housed in retina cells
June 25, 2022
A team of investigators at Flinders University in Australia have found that a specific cell within the retina appears to be particularly good at housing Ebola and other viruses.
Approaches for managing treatment of patients with endophthalmitis
June 22, 2022
Via four cases, Dr Harry Flynn describes a variety of endophthalmitis management options for retinal surgeons.
ARMOR study: Evaluating antibiotic resistance in the treatment of staph infections
June 18, 2022
Dr Penny Asbell discusses her presentation entitled, “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."
Bringing biologics to eye health: Regenerative medicine for inflammatory disorders
June 07, 2022
Biologic treatments can be utilised to help the eye heal itself in inflammatory conditions such as dry eye disorder.
Cost of treatment discourages adherence for patients with dry eye disease associated with Sjögren’s syndrome
May 28, 2022
In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment. Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.
Investigating efficacy of OC-02 to stimulate the trigeminal nerve for the treatment of dry eyes
May 23, 2022
The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.
Strategic alliance combines resources to develop treatment option for dry eye syndrome
May 18, 2022
BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).
Acute and chronic care required for eye with SJS/TEN ocular involvement
May 11, 2022
Patients are at risk for developing severe dry eye and ocular surface disease.